Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass

N. Kinouchi, Y. Ohsawa, N. Ishimaru, Hideyo Ohuchi, Y. Sunada, Y. Hayashi, Y. Tanimoto, K. Moriyama, S. Noji

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

RNA interference (RNAi) offers a novel therapeutic strategy based on the highly specific and efficient silencing of a target gene. Since it relies on small interfering RNAs (siRNAs), a major issue is the delivery of therapeutically active siRNAs into the target tissue/target cells in vivo. For safety reasons, strategies based on vector delivery may be of only limited clinical use. The more desirable approach is to directly apply active siRNAs in vivo. Here, we report the effectiveness of in vivo siRNA delivery into skeletal muscles of normal or diseased mice through nanoparticle formation of chemically unmodified siRNAs with atelocollagen (ATCOL). ATCOL-mediated local application of siRNA targeting myostatin, a negative regulator of skeletal muscle growth, in mouse skeletal muscles or intravenously, caused a marked increase in the muscle mass within a few weeks after application. These results imply that ATCOL-mediated application of siRNAs is a powerful tool for future therapeutic use for diseases including muscular atrophy.

Original languageEnglish
Pages (from-to)1126-1130
Number of pages5
JournalGene Therapy
Volume15
Issue number15
DOIs
Publication statusPublished - Aug 2008
Externally publishedYes

Fingerprint

Myostatin
Small Interfering RNA
Skeletal Muscle
Muscular Atrophy
Therapeutic Uses
RNA Interference
atelocollagen
Nanoparticles
Safety
Muscles
Growth

ASJC Scopus subject areas

  • Genetics

Cite this

Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. / Kinouchi, N.; Ohsawa, Y.; Ishimaru, N.; Ohuchi, Hideyo; Sunada, Y.; Hayashi, Y.; Tanimoto, Y.; Moriyama, K.; Noji, S.

In: Gene Therapy, Vol. 15, No. 15, 08.2008, p. 1126-1130.

Research output: Contribution to journalArticle

Kinouchi, N, Ohsawa, Y, Ishimaru, N, Ohuchi, H, Sunada, Y, Hayashi, Y, Tanimoto, Y, Moriyama, K & Noji, S 2008, 'Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass', Gene Therapy, vol. 15, no. 15, pp. 1126-1130. https://doi.org/10.1038/gt.2008.24
Kinouchi, N. ; Ohsawa, Y. ; Ishimaru, N. ; Ohuchi, Hideyo ; Sunada, Y. ; Hayashi, Y. ; Tanimoto, Y. ; Moriyama, K. ; Noji, S. / Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. In: Gene Therapy. 2008 ; Vol. 15, No. 15. pp. 1126-1130.
@article{9ff9e89514c44c9894357129fc7d023a,
title = "Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass",
abstract = "RNA interference (RNAi) offers a novel therapeutic strategy based on the highly specific and efficient silencing of a target gene. Since it relies on small interfering RNAs (siRNAs), a major issue is the delivery of therapeutically active siRNAs into the target tissue/target cells in vivo. For safety reasons, strategies based on vector delivery may be of only limited clinical use. The more desirable approach is to directly apply active siRNAs in vivo. Here, we report the effectiveness of in vivo siRNA delivery into skeletal muscles of normal or diseased mice through nanoparticle formation of chemically unmodified siRNAs with atelocollagen (ATCOL). ATCOL-mediated local application of siRNA targeting myostatin, a negative regulator of skeletal muscle growth, in mouse skeletal muscles or intravenously, caused a marked increase in the muscle mass within a few weeks after application. These results imply that ATCOL-mediated application of siRNAs is a powerful tool for future therapeutic use for diseases including muscular atrophy.",
author = "N. Kinouchi and Y. Ohsawa and N. Ishimaru and Hideyo Ohuchi and Y. Sunada and Y. Hayashi and Y. Tanimoto and K. Moriyama and S. Noji",
year = "2008",
month = "8",
doi = "10.1038/gt.2008.24",
language = "English",
volume = "15",
pages = "1126--1130",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "15",

}

TY - JOUR

T1 - Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass

AU - Kinouchi, N.

AU - Ohsawa, Y.

AU - Ishimaru, N.

AU - Ohuchi, Hideyo

AU - Sunada, Y.

AU - Hayashi, Y.

AU - Tanimoto, Y.

AU - Moriyama, K.

AU - Noji, S.

PY - 2008/8

Y1 - 2008/8

N2 - RNA interference (RNAi) offers a novel therapeutic strategy based on the highly specific and efficient silencing of a target gene. Since it relies on small interfering RNAs (siRNAs), a major issue is the delivery of therapeutically active siRNAs into the target tissue/target cells in vivo. For safety reasons, strategies based on vector delivery may be of only limited clinical use. The more desirable approach is to directly apply active siRNAs in vivo. Here, we report the effectiveness of in vivo siRNA delivery into skeletal muscles of normal or diseased mice through nanoparticle formation of chemically unmodified siRNAs with atelocollagen (ATCOL). ATCOL-mediated local application of siRNA targeting myostatin, a negative regulator of skeletal muscle growth, in mouse skeletal muscles or intravenously, caused a marked increase in the muscle mass within a few weeks after application. These results imply that ATCOL-mediated application of siRNAs is a powerful tool for future therapeutic use for diseases including muscular atrophy.

AB - RNA interference (RNAi) offers a novel therapeutic strategy based on the highly specific and efficient silencing of a target gene. Since it relies on small interfering RNAs (siRNAs), a major issue is the delivery of therapeutically active siRNAs into the target tissue/target cells in vivo. For safety reasons, strategies based on vector delivery may be of only limited clinical use. The more desirable approach is to directly apply active siRNAs in vivo. Here, we report the effectiveness of in vivo siRNA delivery into skeletal muscles of normal or diseased mice through nanoparticle formation of chemically unmodified siRNAs with atelocollagen (ATCOL). ATCOL-mediated local application of siRNA targeting myostatin, a negative regulator of skeletal muscle growth, in mouse skeletal muscles or intravenously, caused a marked increase in the muscle mass within a few weeks after application. These results imply that ATCOL-mediated application of siRNAs is a powerful tool for future therapeutic use for diseases including muscular atrophy.

UR - http://www.scopus.com/inward/record.url?scp=47549101861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47549101861&partnerID=8YFLogxK

U2 - 10.1038/gt.2008.24

DO - 10.1038/gt.2008.24

M3 - Article

C2 - 18323791

AN - SCOPUS:47549101861

VL - 15

SP - 1126

EP - 1130

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 15

ER -